Neurontin Class Action To Include Generics Buyers

Law360, New York (March 24, 2008, 12:00 AM EDT) -- A Philadelphia judge has ruled that Pfizer Inc. can be held liable for off-label marketing of generic versions of its blockbuster epilepsy drug Neurontin, allowing a class action including people who bought both brand-name and generic Neurontin to go forward.

On March 14, Judge Mark Bernstein of the Philadelphia County Court of Common Pleas denied a motion by Pfizer for partial summary judgment that a class action against it could not include patients who were prescribed gabapentin, the generic version of Neurontin. Judge Bernstein cited several...
To view the full article, register now.